Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study that is studying the rate of red blood cell (RBC)
transfusion rates after planned heart (cardiac) surgery. The study will be conducted at
Barnes-Jewish Hospital.
Cardioplegia refers to the method of stopping (arresting) the heart in order to perform heart
surgery. However, cardioplegia has also come to refer to the solution to achieve cardiac
arrest as well as the machinery in which to deliver the solution. This study will investigate
our current Standard Cardioplegia (diluted 4:1 blood cardioplegia) versus Microplegia
(undiluted blood cardioplegia) to determine if Microplegia reduces peri-operative blood
transfusion rates as compared to Standard Cardioplegia. All forms of cardioplegia will be
delivered using the MPS2 Microplegia delivery machine by Quest Medical, Inc.
Patients will be randomized to receive undiluted microplegia or standard 4:1 cardioplegia.
The patient and the surgeon will be blinded to the randomization.
Patients will be followed for 30 days post-operatively (or until their initial standard of
care post-operative follow up visit with cardiac surgery if that appointment falls outside of
the 30 day post-operative window) for the development of any adverse events as well as
documentation of blood products given.
We will draw one tube of blood for troponin levels at four time points; 1 draw before surgery
(this may be done during the intraoperative period), and 3 draws post-operatively: ICU
arrival, 12 hours post-ICU arrival and 24 hours post-ICU arrival. This is to closely monitor
the patient for any heart tissue injury.